In this respect, clinical treatment of RCC lags behind other cancers for which molecular knowledge is invaluable in guiding clinical decisions (e.g. hormone receptors or human epidermal growth factor receptor 2 (HER2) status in breast cancer). The gene discussed is ERBB2; the disease is cancer.